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Critical periods of increased fetal vulnerability to
a maternal high fat diet
Maria del Mar Plata1, Lyda Williams2, Yoshinori Seki2, Kirsten Hartil2, Harpreet Kaur1, Chia-Lei Lin2, Ariana Fiallo2,
Alan S Glenn2, Ellen B Katz2, Mamta Fuloria1, Maureen J Charron2,3,4* and Patricia M Vuguin1,5*
Abstract
Background: Fetal adaptations to high fat (HF) diet in utero (IU) that may predispose to Metabolic Syndrome
(MetS) in adulthood include changes in fetal hepatic gene expression. Studies were performed to determine
whether maternal exposure to HF diet at different stages during pregnancy had different effects on the fetus,
including hepatic gene expression.
Methods: Female wild type mice were fed either a HF or breeding chow (C) for 2 wks prior to mating. The
experimental groups were composed of embryonic day (e) 18.5 fetuses obtained from WT female mice that were
fed HF (HF, 35.5% fat) or breeding chow (C, 9.5% fat) for 2 wk before mating until e9.5 of pregnancy
(periconception-midpregnancy). At e9.5 dams were switched to the opposite diet (C-HF or HF-C).
Results: Exposure to HF diet throughout pregnancy reduced maternal weight gain compared to C diet (p < 0.02 HF vs.
C). HF-C dams had significantly decreased adiponectin levels and litter size when compared to C-HF (p < 0.02 HF-C vs
C-HF). Independent of the timing of exposure to HF, fetal weight and length were significantly decreased when
compared to C diet (HF, C-HF and HF-C vs. C p < 0.02). HF diet during the second half of pregnancy increased
expression of genes in the fetal liver associated with fetal growth (C-HF vs C p < 0.001), glucose production (C-HF vs C
p < 0.04), oxidative stress and inflammation (C-HF vs C p < 0.01) compared to C diet.
Conclusions: This model defines that there are critical periods during gestation in which the fetus is actively shaped
by the environment. Early exposure to a HF diet determines litter size while exposure to HF during the second half of
pregnancy leads to dysregulation of expression of key genes responsible for fetal growth, hepatic glucose production
and oxidative stress. These findings underscore the importance of future studies designed to clarify how these critical
periods may influence future risk of developing MetS later in life.
Background
Epidemiological as well as animal data has demonstrated
that fetal and early postnatal periods are important for
determining the future risk of developing Metabolic
Syndrome (MetS), regardless of genetic or additional envir-
onmental exposures. The process by which “insults at crit-
ical stages of development” lead to permanent changes in
tissue structure or function that adversely affect physio-
logical functions in adult life is known as the Developmen-
tal Origins of Health and Disease (DOHaD) [1,2].
Pregnancy and lactation are critical periods where ma-
ternal diet plays an important role in fetal development
and the development of MetS [2-4]. Poor dietary choices
during pregnancy are more likely to be encountered in
groups with less education and lower socioeconomic sta-
tus (SES) [5-7].
A Western Style diet, mostly high fat diet (HF) during
pregnancy (in utero, IU) is associated with low, normal as
well as increase birth weight [8-11]. In both humans and
animals, many studies investigating the effects of HF in
utero are complicated by the occurrence of confounding
variables such as maternal obesity or gestational diabetes
that also influence birth weight or the development of
MetS in the offspring [12-14].
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Fetal growth involves a carefully orchestrated cascade by
which each organ develops throughout gestation. Insulin,
glucocorticoids, Insulin-like Growth Factors (IGFs) and
their regulatory binding proteins (IGFBPs) play an im-
portant role in fetal growth and development, which are
regulated by maternal nutrient availability and maternal
metabolic milieu [15,16]. Poor prenatal growth, as seen
in babies born small for gestational age (SGA), is associ-
ated with an increase in inflammation and oxidative
stress at birth and insulin resistance in prepubertal chil-
dren [17,18] and is known to increase the risk of devel-
oping cardiovascular disease and impaired glucose
tolerance in adulthood [19,20].
Poor prenatal growth, an inflammatory-oxidative stress
response, lipotoxicity in the liver and dysregulation in the
hepatic expression of genes involved in gluconeogenesis
(GNG) have also been observed in non-human primates
as well as rodent models exposed to HF IU [9,10,21,22].
Similarly, our laboratory has previously reported that WT
mice exposed to HF IU are born small, have altered pan-
creatic islet morphology [23] and develop features of MetS
compared to mice exposed to control (C) diet IU and dur-
ing lactation [9]. Fetal liver of mice exposed to HF IU have
increased expression of genes involved in GNG, inflam-
mation and oxidative stress [10] that were associated with
functional alterations to fetal hepatic histone modifica-
tions [24]. These modifications persisted up to 5 weeks of
age [24], suggesting that prenatal exposures by themselves
will lead to permanent adaptations with lasting effects on
metabolic mechanisms.
The timing of the insult has the potential to critically
influence the development and function of any particular
organ. For example, it is known that during placental de-
velopment, disruption during a period of angiogenesis
will have different consequences compared to disruption
during a period of growth and differentiation [25].
The aim of this study was to investigate the changes that
occur in the fetus, particularly in the expression of genes
in the fetal liver that are involved in fetal growth, hepatic
glucose production, oxidative stress and inflammation,
after exposure to a HF diet during specific periods of ges-
tation. Defining the periods of increased vulnerability dur-
ing fetal development to environmental programming will
reveal windows of opportunity in which treatments may
have increased likelihood for a positive outcome in the off-
spring. This is important as women of lower SES, at the
greatest risk of malnutrition, do not access health care
until they are already pregnant [26].
Methods
Animals and Experimental Design: All studies were ap-
proved by the Institutional Animal Care and Use Com-
mittee at Albert Einstein College of Medicine, in
accordance with Animal Welfare Act guidelines. Twelve
to 14 week old wild-type (WT) female mice (CD1 back-
ground) were maintained on control diet (C; Pico Lab®
Mouse Diet \#5058; 9% fat), or switched to high fat (HF;
Bio-Serv Product #F3282; 35.5% fat as lard) diet during
the periconceptional period, 2 weeks prior to mating. Fe-
males were bred to non-littermate glucose transporter 4
heterozygous (G4+/−) males, a model of insulin resistance
[27]. In contrast to WT male offspring from WT pregnan-
cies, WT male offspring of WT female and G4+/− male
exposed to a maternal HF IU are programmed to develop
characteristics of the MetS [9,10,23].
Pregnancy was determined by the presence of a copula-
tory plug and defined as embryonic day 0.5 (e0.5). Four
experimental groups were studied (Figure 1). Pregnant fe-
males were kept on the same diet throughout periconcep-
tion and pregnancy (C: n = 10; HF: n = 8) or, to identify
the critical period in which exposure to HF diet may affect
fetal growth or development, dams were switched at mid-
pregnancy (embryonic day, e9.5) to the opposite diet
(C-HF: n = 5; HF-C: n = 8). Mid pregnancy was chosen
because full expression of key enzymes and transcription
factors involved in insulin signaling are present from mid
pregnancy or embryonic day 9.5 onward [28].
Maternal Phenotypic Evaluation: Body weight gain
[(BW day X - BW e0.5)/BW day mating e18.5] x 100)] in
pregnant females was determined (C: n = 10; HF: n = 8;
C-HF: n = 5; HF-C: n = 8) as previously described [9].
Metabolic phenotype of each mother was determined at
the time of sacrifice (Table 1). Blood glucose concentra-
tions were measured using a glucometer (Precision Q.I.D.,
a gift from Abbott Laboratories, Chicago, IL). Commer-
cially available kits were used for measuring levels of
plasma insulin, adiponectin, (Linco Research, St. Charles,
MO), non-esterified fatty acids (NEFAs) (Wako Chemi-
cals, Neuss, Germany), and glucose (Sigma Chemical Co.,
St. Louis, MO) [9,10].
Fetal Study: Pregnant mothers and fetuses were sacri-
ficed at e18.5 of pregnancy, as previously described
[9,10,23]. Litter number, placental and fetal weights, and
crown-rump length (CRL) were recorded, as well as the
number of abnormal or dead pups per litter. Fetuses (C:
n = 33: HF: n = 53; C-HF: n = 32: HF-C: n = 43) were eu-
thanized by cervical dislocation immediately following
dissection from the uterine horn. Fetal plasma was col-
lected and pooled based on diet and genotype. Fetal
livers were dissected and frozen in liquid nitrogen and
stored at -80°C until analyzed. Genotyping and sex de-
termination of fetuses were performed as previously de-
scribed [9]. G4+/− and WT fetuses had similar adaptive
response to a HF IU, but WT fetuses were the focus of
this study because they exhibit the most profound meta-
bolic complications and also to eliminate the potential
confounding effects of genetic factors during fetal devel-
opment [9,10].
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Quantitative Real Time-PCR Analysis: The cDNA of
fetal livers was analyzed with qRT PCR for mRNA gene
expression (n = 4-6 per diet) as previously described
[10,23]. The RNA was checked for DNA contamination,
using PCR with control primers as described previously
[29]. Three common housekeeping genes, ubiquitin, b-
actin (ACTB), cyclophillin b were used for normalization.
For quantitative analysis, all samples were normalized to
the genes described above using the ΔCT value method;
the control (C) group was used as the reference group.
Each sample was measured in triplicate for each gene to
assess technical variability [10,23,29]. The selection of
genes was based on a literature search for genes associated
with an altered IU milieu [10]. Sequence-specific primer
pairs have been previously provided. Sample size was cal-
culated to detect a 1.5 to 4 fold change in expression level
of the gene of interest based on prior findings [10,23].
Statistical Analysis: Data are presented as the mean ±
SEM. Statistical analyses were performed using JMP 7.0
software (SAS Institute, Cary, NC) or Graph Pad Prism
software version 5.04 for Windows (Graph Pad
Software, San Diego, California). ANOVA was used to
test the difference between the means of two (t-test) or
more groups and Bonferroni’s post-hoc analysis was
Figure 1 Study design and groups based on maternal diet. Control (C), High Fat (HF), Control – High Fat (C-HF) and High Fat – Control
(HF-C); N = 5-10/group diet.
Table 1 Maternal metabolic phenotype
C HF C-HF HF-C
N 10 8 5 8
Maternal Weight at Plug Day (g) 35.9 ±1.8A 36.7 ± 1.4A 35.4 ± 2.1A 35.1 ± 2.9A
Maternal Weight at e9.5 (g) 44.3 ± 4.0A 39.6 ± 3.1A 44.3 ± 1.4A 41.7 ± 4.8A
Maternal Weight at Sacrifice (g) 62.6 ± 3.6AB 51.9 ± 2.8B 56.3 ± 1.6AB 64.7 ± 6.1A
Maternal Weight Gain Throughout the Pregnancy (g) 28.3 ± 1.9A 18.2 ± 2.0B 20.9 ± 1.4AB 24.9 ± 3.7AB
Renal Fat (g) 0.6 ± 0.2A 0.6 ± 0.2A 0.5 ± 0.2A 1.3 ± 0.4A
Gonadal Fat (g) 1.1 ± 0.4A 1.3 ± 0.4A 1.4 ± 0.3A 1.9 ± 0.6A
Visceral Fat (g) 1.7 ± 0.6A 1.9 ± 0.6A 1.9 ± 0.6A 3.3 ± 0.9A
Liver (g) 2.3 ± 0.1A 2.2 ± 0.1A 2.3 ± 0.1A 2.5 ± 0.2A
Liver/BW 0.036 ± 0.002A 0.042 ± 0.002A 0.041 ± 0.002A 0.039 ± 0.004A
Heart (g) 0.20 ± 0.02A 0.17 ± 0.02A 0.19 ± 0.02A 0.21 ± 0.01A
Heart/BW 0.0033 ± 0.0002A 0.0033 ± 0.0003A 0.0035 ± 0.0003A 0.0034 ± 0.0003A
Adiponectin (ng/ml) 21.9 ± 2.8AB 20.6 ± 5.1AB 27.4 ± 3.5A 12.5 ± 1.8B
NEFAs (mg/dl) 2.4 ± 0.2B 3.1 ± 0.2A 2.3 ± 0.3AB 1.7 ± 0.3B
Glucose (mg/dl) 127 ± 2A 127 ± 5A 119 ± 5A 134 ± 7A
Insulin (pg/ml) 2.3 ± 0.6A 1.9 ± 0.1A 1.3 ± 0.1A 2.0 ± 0.1A
Data which are significantly different from each other are denoted by different letters (p < 0.02). All data are presented as the mean ± SEM.
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performed. When appropriate, the Mann–Whitney two
tailed T-test was utilized. A linear regression model was
used to determine the effect of sex on fetal BW, CRL
and placental weight, and fetal glucose levels [10]. To
determine cohort size a standard power calculation was
performed based on previous findings [9,10,23]. Accept-
able study power was agreed a priori to be ≥80% (type-I
error of ≤0.20). P < 0.05 was considered statistically
significant.
Results
HF diet during pregnancy alters maternal weight gain
HF dams gained significantly less weight when compared
to C (p < 0.02). C-HF dams tended to gain less weight
compared to C, although this did not reach statistical sig-
nificance (p < 0.07). HF exposure during the first half of
pregnancy (HF-C) did not affect maternal weight gain.
Maternal liver, heart, renal, visceral fat pad weights (renal
and gonadal fat pad) and organ/BW ratios did not differ
between the four groups (Table 1).
HF diet during the first half of pregnancy alters maternal
serum adiponectin levels
HF-C dams had decreased adiponectin levels when com-
pared to C-HF (p < 0.02); although there was a trend,
this did not reach statistical significance when compared
to C dams (p < 0.06). Consumption of a HF diet during
pregnancy did not affect insulin and glucose levels in the
mothers, but significantly increased serum NEFA levels
when compared to C and HF-C (p < 0.01) (Table 1).
HF diet during the first half of pregnancy reduces litter
weight
HF-C dams had significantly smaller litters when com-
pared to the other groups (HF-C vs C p < 0.004; HF-C vs.
HF p < 0.02; HF-C vs. C-HF p < 0.02). The number of re-
sorption sites was not significantly different between the
four groups, but there was a tendency in the HF-C group
to have more resorption sites compared to C and C-HF
(HF-C vs. C p = 0.07; HF-C vs. C-HF p = 0.07) (Table 2).
HF diet during pregnancy stunts fetal growth without
altering placental weight
Exposure to HF at any point during pregnancy was
associated with an 8 to 14% decrease in body weight
(HF vs. C p < 0.0001; C-HF vs. C p < 0.0001; HF-C vs. C
p < 0.02). Of all the HF groups, C-HF had the lowest
body weight. HF reduced length (CRL) in all groups (HF
vs. C p < 0.004; C-HF vs. C p < 0.02; HF-C vs. C p <
0.004). The decrease was similar in all HF groups com-
pared to the control group (8%). HF exposure did not
alter placental weight when compared to the C group.
Decreased BW with no corresponding change in placen-
tal weight resulted in an increase in placenta:BW ratio
in groups exposed to HF at any point during gestation
(HF vs C p < 0.004; C-HF vs C p < 0.002; HF-C vs C p <
0.04). No differences in body weight (p = 0.2), placental
weight (p = 0.7) or CRL (p = 0.9) was found when the
data was analyzed based on fetal sex (Table 2).
HF diet during the second half of pregnancy results in
increased hepatic expression of genes associated with
fetal growth
Exposure to HF throughout pregnancy increased the hep-
atic gene expression of insulin-like growth factor 1 (IGF1)
(p < 0.0001), insulin-like growth factor 1 receptor (IGF1R)
(p < 0.001), and insulin-like growth factor binding protein
1 (IGFBP1) (p < 0.0001), genes involved in fetal growth
when compared to the C diet. Hepatic IGF1 and IGFBP1
gene expression was significantly higher in HF fetuses
when compared to the C-HF (p < 0.001) and HF-C group
(p < 0.0001) (Figure 2).
Exposure to a HF diet during the second half of preg-
nancy (C-HF) significantly increased the hepatic gene
expression of IGF1 (p < 0.01), IGF1R (p < 0.01) and
insulin-like growth factor 2 (IGF2) (p < 0.01) when com-
pared to the C group. Hepatic IGF1 (p < 0.01), IGF2
(p < 0.01) and IGFBP1 (p < 0.01) gene expression was
significantly higher in C-HF fetuses when compared to
the HF-C group. Interestingly, although expression of
IGF1 was increased in C-HF compared with C group, its
expression was decreased compared with HF fetuses
(p < 0.05) (Figure 2).
The expression of genes involved in fetal growth in
HF-C was similar to C fetuses (Figure 2).
HF diet during the second half of pregnancy increases
fetal serum glucose levels and expression of genes
associated with hepatic glucose production (HGP)
Control, HF and HF-C fetuses were euglycemic while
C-HF fetuses had a significant increase in their glucose
levels when compared to all the other groups (p < 0.03).
No differences in fetal glucose levels were found when the
data was analyzed based on fetal sex (p = 0.8) (Table 2).
Exposure to a HF diet throughout pregnancy (HF) sig-
nificantly increased the expression of hepatic genes
associated with glucose metabolism such as phospho-
enolpyruvate carboxylase (PEPCK) (p < 0.04) and glu-
cose 6-phosphatase (G6Pase) (p < 0.01), rate-limiting
enzymes of GNG; glycogen synthase kinase alpha
(GSK3a) (p < 0.01), a rate-limiting enzyme of glycogen-
olysis; NAD+ −dependent protein deacetylase (SIRT1)
(p < 0.002), a PGC1α activator that regulates expression
of GNG genes; and Forkhead Box Protein A2 (FOXA2)
(p < 0.003), a transcription factor that regulates the ex-
pression of genes such as PEPCK when compared to a C
diet. Hepatic GSK3a (p < 0.01) and SIRT1 (p < 0.01)
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gene expression were significantly elevated in the HF fe-
tuses when compared to HF-C group (Figure 3).
Exposure to a HF diet during the second half of preg-
nancy (C-HF) significantly increased the hepatic gene
expression of G6Pase (p < 0.01), GSK3a (p < 0.01), and
SIRT1 (p < 0.01) when compared to a C diet. Hepatic
GSK3a (p < 0.01) and SIRT1 (p < 0.01) gene expression
were significantly elevated in the C-HF fetuses when
compared to HF-C group (Figure 3).
The pattern of expression of genes involved in glucose
metabolism in HF-C fetuses was similar to C fetuses.
Gene expression of glucose transporter 2 (GLUT2),
glycogen synthase kinase beta (GSK3b) and insulin receptor
(INSR) which encode proteins that participate in hepatic
glucose metabolism were not significantly affected by the
diet (Table 3).
HF diet during the second half of pregnancy results in
increased hepatic expression of genes associated with
oxidative stress and inflammation in the fetus
Exposure to a HF diet throughout pregnancy (HF) sig-
nificantly increased the expression of hepatic genes as-
sociated with inflammation such as nuclear factor kappa
B 1 (NFKB1) (p < 0.001), heme oxygenase 1 (HMOX1)
(p < 0.001), musculoaponeurotic fibrosarcoma oncogene
homolog F (MAFF) (p < 0.001), cytokine signaling pro-
tein 3 (SOCS3) (p < 0.01), dual specificity protein phos-
phatase 1 (DUSP1) (p < 0.01), and inhibitor of DNA
binding 1 (ID1) (p = 0.0001) when compared to a C and
HF-C diet. Hepatic HMOX1 (p < 0.001), DUSP1 (p <
0.01) and ID1 (p < 0.01) gene expression were signifi-
cantly elevated in the HF fetuses when compared to C-
HF group (Figure 4).
Table 2 Metabolic phenotype of fetuses at e18.5
C HF C-HF HF-C
N 33 53 32 43
Total Litter Weight (g) 16.9 ± 2.2A 12.9 ± 1.0AB 13.9 ± 1.9AB 11.6 ± 1.1B
Number of Pups per Litter 12.0 ± 1.6A 11.0 ± 0.7A 11.6 ± 0.3A 9.0 ± 0.3B
Resorption Sites per Litter 1.8 ± 0.2A 2.5 ± 0.3A 1.7 ± 0.6A 3.5 ± 1.5A
Fetal BW (g) 1.40 ± 0.02A 1.24 ± 0.01BC 1.21 ± 0.02C 1.30 ± 0.03B
Fetal CRL (cm) 2.55 ± 0.03A 2.43 ± 0.03B 2.44 ± 0.03B 2.43 ± 0.03B
Placental Weight (g) 0.107 ± 0.004A 0.109 ± 0.004A 0.110 ± 0.005A 0.111 ± 0.003A
Placenta:BW ratio 0.076 ± 0.003A 0.089 ± 0.003B 0.092 ± 0.004B 0.086 ± 0.003B
Fetal Glucose (mg/dl) 57.6 ± 3.0A 63.2 ± 4.5A 82.1 ± 7.8B 64.9 ± 5.0A
Data which are significantly different from each other are denoted by different letters (p < 0.02). All data are presented as the mean ± SEM.
Figure 2 Relative mRNA Expression of Growth Factors in Fetal Liver at e18.5. Changes in mRNA expression of genes were determined by
qRT-PCR. N = 4-6/diet group. Data points which are significantly different from each other are denoted by different letters (p < 0.01). Bars indicate
standard error of the mean. Primer sequences were previously published [10].
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Exposure to a HF diet during the second half of preg-
nancy (C-HF) significantly increased the hepatic gene ex-
pression of HMOX1 (p < 0.01), MAFF (p < 0.01) and
SOCS3 (p < 0.01) when compared to C and HF-C groups.
Similarly, expression of NFKB1 was increased in C-HF fe-
tuses when compared to HF-C (p < 0.01) (Figure 4).
The pattern of expression of genes involved in inflamma-
tion in HF-C fetuses was similar to the C group (Figure 4).
HF diet during pregnancy does not alter hepatic
expression of genes associated with cortisol or lipid
metabolism in fetal liver
Exposure to HF at any point during pregnancy did not
affect expression of genes encoding hepatic enzymes that
catalyze cortisol metabolism such as hydroxysteroid (11-
beta) dehydrogenase 1 (HSD11B1) and hydroxysteroid
(11-beta) dehydrogenase 2 (HSD11B2). Hepatic expres-
sion of sterol regulatory element binding transcription
factors 1 and 2 (SREBF1 and SREBF2), transcriptional
activators required for lipid homeostasis, were not sig-
nificantly affected by exposure to HF at any point during
pregnancy (Table 3).
Discussion
Prenatal exposure to a HF diet is associated with in-
creased risk for MetS. Using a previously characterized
mouse model [9,10,22,23], we sought to determine
whether the timing of exposure to maternal HF diet af-
fected fetal growth and expression of hepatic genes
known to influence fetal growth and postnatal insulin re-
sistance and relate it to possible changes in maternal
glucose metabolism.
The timing of exposure to maternal HF resulted in dif-
ferent outcomes with respect to litter size, fetal body
weight, crown rump length, and hepatic gene expression.
These changes were accompanied by differences in ma-
ternal weight gain and adiponectin levels.
Consistent with our previous findings the number of
fetuses was not altered in the group exposed to HF
throughout pregnancy [9,10]. However, a decreased
number of fetuses were observed in HF-C dams com-
pared to all other groups. Decreased number of fetuses
was accompanied with an increase in the number of re-
sorption sites. These findings suggest that the period of
transition from HF to control diet is a critical period in
sustaining embryo survival.
While reduced fetal/birth weight in response to HF IU
has been reported in some studies [21,30,31], other stud-
ies have reported no change [32,33] or increased fetal/
birth weight [34,35]. Some reasons for these discrepan-
cies include: duration of HF exposure; presence/absence
of maternal obesity; diet composition; and species
Figure 3 Relative mRNA Expression of Glucose Production Genes in Fetal Liver at e18.5. Changes in mRNA expression of genes were determined
by qRT-PCR. N = 4-6/diet group. Data points which are significantly different from each other are denoted by different letters (p < 0.04). Bars indicate
standard error of the mean. Primer sequences were previously published [10].
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Table 3 List of genes that were not differentially expressed in fetal liver at e18.5
Gene name Gene symbol Gene sequence (Forward and Reverse) p value
Glycogen-synthase kinase b GSK3b
CGGGACCCAAATGTCAAACT
NS
TCCGAGCATGTGGAGGGATA
Glucose transporter 2 GLUT2
GTGTGCAGCAGCCTGTGT
NS
CAGTGAAGGCCGTGTTGAC
Insulin Receptor INSR
CCTGAAAAGTCACCTCCGTTCT
NS
TTCAAGTATGCCATGCCATCA
Hydroxysteroid (11-beta) dehydrogenase 1 HSD11B1
GGGAAATGACCCAGCCTATG
NS
CGTGGAAAAGAACCCATCCA
Hydroxysteroid (11-beta) dehydrogenase 2 HSD11B2
CGGGCAGTTCCTGAATTCAC
NS
GCATCGATGATGGCATCTACA
Sterol regulatory element binding transcription factor 1 SREBF1
CCAGAGGGTGAGCCTGACAA
NS
AGCCTCTGCAATTTCCAGATCT
Sterol regulatory element binding transcription factor 2 SREBF2
CACCAGCTGCACATCACAG
NS
ACTCGGCCAGGTTCACAG
N = 4-6/diet group; NS = not significant.
Figure 4 Relative mRNA Expression of Genes associated with Oxidative Stress in Fetal Liver at e18.5. Changes in mRNA expression of
genes were determined by qRT-PCR. N = 4-6/diet group; Data points which are significantly different from each other are denoted by different
letters (p < 0.01). Bars indicate standard error of the mean. Primer sequences were previously published [10].
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studied. In this animal model, the dams exposed to a HF
diet at any point during their pregnancy or periconcep-
tion are not obese. When compared to C group HF
dams had a significantly reduced body weight gain.
Despite no significant reduction in maternal weight
gain, fetuses exposed to HF in the second half of preg-
nancy (C-HF) had the lowest body weight at e18.5,
followed by fetuses exposed to HF throughout preg-
nancy (HF). Interestingly, similarly to the BW gain seen
in HF-C dams, fetuses in which the diet was switched
from HF to C during the second half of pregnancy had
an increase in BW compared to HF and C-HF groups.
These data suggests that similar to humans, late preg-
nancy in mice is also the critical period for the most
rapid fetal growth [36]. The data also suggests that ma-
ternal weight gain may not reflect fetal growth.
CRL was significantly reduced in all HF groups. These
data indicate that although the timing of exposure to HF
during pregnancy influences fetal body weight it is not
enough to prevent fetal growth restriction as indicated
by CRL measurements.
Placental weight was not affected by HF diet at any
point during pregnancy. The placenta is a highly efficient
organ that integrates signals from the mother and fetus
and serves to match fetal growth demands [16,37]. The
phenomenon of compensatory placental expansion in in-
fants with low birth weight has been well documented;
however, placental function may not necessarily correl-
ate with placental weight [38]. HF exposure did not alter
placental weight but did decrease fetal body weight, thus
the increase in the placental weight: BW ratio observed
in the HF groups compared to the control group may re-
flect a placental compensatory response to improve nu-
trient transfer. Studies have demonstrated that elevated
placental IGFBP-1 is associated with an increase in the
size of the labyrinth zone, the area of nutrient exchange
in the mouse placenta and an increased placental weight:
BW ratio [39]. Future studies are needed to confirm this
hypothesis.
The greatest changes in maternal weight gain and gene
expression were seen in HF dams and their fetuses sug-
gesting that increased duration of HF exposure elicits a
greater effect. Consumption of a HF diet during preg-
nancy did not affect maternal glucose or insulin levels at
e18.5. However, in addition to having smaller litters, HF-
C dams had decreased adiponectin levels when com-
pared to C-HF dams. In contrast, C, and HF dams had
similar adiponectin levels and litter size. Adiponectin is
secreted from both adipose tissue and placenta [40]. It is
inversely correlated with body fat percentage in adults
and regulates glucose and fatty acid oxidation [41]. In-
creased levels are generally associated with insulin sensi-
tivity. There have been inconsistent reports regarding
adiponectin levels during pregnancy [42,43]. Decreased
adiponectin levels have been seen in gestational diabetes
mellitus while elevated adiponectin levels have been ob-
served with preeclampsia [42,44], suggesting that adipo-
nectin levels are altered during pathological gestations.
Adiponectin can be found in cord blood [45]; therefore
it is plausible that decreased adiponectin levels seen in
HF-C dams could be a link between the altered maternal
metabolic environment and poor pregnancy outcomes
seen in this group. At this point, it is not clear why adi-
ponectin levels were not different among the other
groups.
IGFs and IGFBPs are thought to play an important role
in fetal growth [46]. Liver is the predominant source of
circulating IGFs. IGF2 is the primary growth factor during
embryonic growth, and IGF1 is the dominant growth
regulator during late gestation [47]. Reduced IGF1 action,
due to polymorphisms or heterozygous mutations in IGF1
or the IGF1 receptor (IGF1R), leads to low birth weight
[48]. In humans, IGF1 and IGF2 serum levels are signifi-
cantly reduced in SGA fetuses [49]. HF and C-HF fetuses
were growth restricted despite having increased IGFs and
IGF1R gene expression. A previous study in nutrient
restricted ewes demonstrated increased IGF1 and IGF2 re-
ceptors in adipose tissue despite growth restriction [50].
This may indicate reduced IGF action arising from de-
creased IGF bioavailability (mRNA expression that may
not reflect serum IGF concentration) and/or bioactivity
(IGF resistance or altered IGF signaling).
Interestingly, although expression of IGF1 was in-
creased in C-HF compared with C, its expression was
decreased when compared with HF. This is important to
note because C-HF fetuses have the lowest body weight.
Thus, it is possible that changes in IGF1 expression in
HF fetuses are able to compensate for the differences in
BW seen at e18.5 in both groups, and the lack of in-
creased in the IGF-1 expression C-HF may, in part, ex-
plain reduced BW in this group.
Altered IGF1 signaling has been seen in human pla-
centas from pregnancies with growth restricted fetuses
[51]. These placentas may be viewed as IGF-resistant tis-
sue where IGF1 signaling is blunted due to reduced ex-
pression of the IGF1R; impairment of the IRS-2/
phosphatidyl inositol 3-kinase pathway; and reduced p38
and c-Jun N-terminal kinase activation [51]. In addition,
IGFBP-1 mRNA expression, which was also elevated in
our model and other models of growth restriction [39],
could act as a potent inhibitor of IGFs interacting with
the IGF1R.
Glucose levels were significantly increased in C-HF fe-
tuses. These changes were accompanied by an increase
in hepatic IGF2 expression. Increased IGF2 expression
in the fetal liver has been associated with fetal undernu-
trition [52] and neonatal diabetes [53], and possible HF
feeding during pregnancy [54]. Increased IGF2 mRNA
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levels have been associated with impaired placental nu-
trient transport [55], suggesting that the elevated glucose
levels seen in the C-HF model may represent an increase
in fetal hepatic glucose production as an adaptive re-
sponse to a reduced placental nutrient transport.
The principal cause of fasting hyperglycemia in T2DM,
a disease burden for SGA babies, is hepatic insulin
resistance leading to unsuppressed GNG [18]. Although
changes in hepatic GNG may not be directly inferred from
gene expression data [56], the observed alterations in the
gene expression, (PEPCK, G6P and GSK3a) seen with C-
HF are consistent with increased hepatic glucose produc-
tion and may, in part, explain the observed increase in
fetal glucose levels. In addition, HF exposure increased
hepatic SIRT1 expression. SIRT1 is an important regulator
of hepatic GNG [57], and increased expression of SIRT1
may contribute to the increased glucose levels observed in
C-HF fetuses.
Activation of glucose production in response to HF may
be an adaptive response to maternal malnutrition or im-
paired placental nutrient transport or may represent hep-
atic insulin resistance. Insulin is the dominant mechanism
for suppressing GNG gene expression and glucose pro-
duction [58]. We previously demonstrated that HF expos-
ure does not alter insulin levels under basal conditions
[10]. Although we did not investigate the phosphorylation
status of proteins downstream of the insulin receptor such
as V-akt murine thymoma viral oncogene homolog 1
(Akt) or GSK3, mRNA expression of GLUT2 and the in-
sulin receptor, two important components of the insulin
signaling pathway, were not altered suggesting normal
hepatic insulin action. Thus, it is possible that the in-
creased glucose levels seen in the C-HF model may not re-
flect hepatic insulin resistance [59] but reflect either
increased hepatic glucose production or decreased periph-
eral glucose disposal. Mechanistic studies in isolated fetal
hepatocytes are needed to test these hypotheses. In con-
trast to the C-HF fetuses, HF fetuses have normal glucose
levels. Thus, it is plausible that the elevated glucose levels
seen in C-HF when compared to the HF fetuses were a re-
sponse to the acute change in the diet.
Inflammatory cytokines are a proposed link between
obesity, insulin resistance and metabolic disease [60].
Studies in non-human primates [21] and mice [10] ex-
posed to a maternal HF diet show that fetuses are SGA
and develop an inflammatory-oxidative stress response
and liver lipotoxicity compared to controls exposed to a
normal diet. The expression of genes associated with cel-
lular stress and inflammation (MAFF, HMOX1, DUSP1,
SOCS3, ID1) in the HF and C-HF fetal liver are consist-
ent with these studies and suggest a mechanism where
exposure to HF, either throughout pregnancy or during
the second half of pregnancy, increases the risk of MetS
in later life [10,21].
The expression of key enzymes and transcription fac-
tors involved in insulin signaling is turned on during the
second half of pregnancy [28]. Therefore, late gestation
may represent a critical window during hepatic develop-
ment when exposure to HF may have a profound impact
on the future metabolism of the offspring [61]. Although
many of the changes observed by exposure to HF in the
second half of pregnancy were similar to those observed
in fetuses exposed to HF throughout pregnancy, future
studies to clarify the long-term implications of the differ-
ent exposures are warranted.
One question that still remains is whether HF expos-
ure during the second half of pregnancy is enough to
program MetS in the offspring or if the offspring needs
to be continuously exposed to HF throughout pregnancy
and lactation. Although the current studies do not an-
swer this question, our previous findings have demon-
strated that some histone modifications that occur in
fetal livers in response to HF exposure persist up to
5 weeks of age [24].
Conclusions
In conclusion, exposure to HF diet during the first half
of pregnancy determines litter size while exposure to HF
during the second half of pregnancy leads to dysregula-
tion of expression of key genes responsible for fetal
growth, hepatic glucose production and oxidative stress;
some of these changes seem to be exacerbated by the
length of the HF exposure. Whether these alterations
contribute to the increased susceptibility of MetS in
adulthood remains to be determined, but our findings
suggest that dietary modifications made during preg-
nancy can prevent alterations in hepatic gene expression
that are associated with MetS.
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